Bruder D, Darji A, Gakamsky D M, Chakraborty T, Pecht I, Wehland J, Weiss S
Department of Cell Biology and Immunology, GBF, National Research Center for Biotechnology, Braunschweig, Germany.
Eur J Immunol. 1998 Sep;28(9):2630-9. doi: 10.1002/(SICI)1521-4141(199809)28:09<2630::AID-IMMU2630>3.0.CO;2-Z.
The property of listeriolysin (LLO) to introduce soluble passenger proteins into the cytosol of antigen-presenting cells allows the induction of CD8+ cytotoxic T cells against such antigens. To overcome the potential problem of presentation of the immunodominant epitope LL091-99 by H-2Kd, a variant LLO92A was established in which Tyr 92 was replaced by Ala. Immunization of BALB/c mice with purified LLO92A failed to stimulate cytotoxic T cells specific for either the epitope LLO91-99 or for any other LLO-derived peptide. Injection of mixtures of purified LLO92A and soluble nucleoprotein (NP) of influenza virus into mice resulted in a strong cytotoxic T cell response exclusively directed against NP. The LLO92A variant was successfully used to generate, propagate and characterize a CD8 T cell line specific for the membrane-bound virulence factor ActA of Listeria monocytogenes. Interestingly, wildtype ActA bound to the surface of live L. monocytogenes was not presented by MHC class I molecules to the CD8+ T cell line.
溶血素(LLO)将可溶性“乘客”蛋白导入抗原呈递细胞胞质溶胶的特性,使得能够诱导针对此类抗原的CD8 + 细胞毒性T细胞。为克服H-2Kd对免疫显性表位LL091-99的呈递这一潜在问题,构建了一种变体LLO92A,其中第92位酪氨酸被丙氨酸取代。用纯化的LLO92A免疫BALB / c小鼠未能刺激针对表位LLO91-99或任何其他LLO衍生肽的特异性细胞毒性T细胞。将纯化的LLO92A与流感病毒可溶性核蛋白(NP)的混合物注射到小鼠体内,导致仅针对NP的强烈细胞毒性T细胞反应。LLO92A变体成功用于产生、增殖和鉴定针对单核细胞增生李斯特菌膜结合毒力因子ActA的CD8 T细胞系。有趣的是,与活的单核细胞增生李斯特菌表面结合的野生型ActA未被MHC I类分子呈递给CD8 + T细胞系。